Copyright
©The Author(s) 2025.
World J Diabetes. Dec 15, 2025; 16(12): 112694
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.112694
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.112694
Figure 1 Flow diagram describing identification of cases and propensity-matched controls.
EGD: Esophagogastroduodenoscopy; GLP-1RA: Glucagon-like peptide-1 receptor agonist; T2DM: Type 2 diabetes mellitus; DPP4: Dipeptidyl peptidase 4; DPP4i: Dipeptidyl peptidase 4 inhibitor; UGI: Upper gastrointestinal; BMI: Body mass index; DM: Diabetes mellitus; HbA1c: Hemoglobin A1c.
- Citation: Oh YE, Kim TS, Chi SA, Park HJ, Min YW, Lee H, Lee JH, Rhee PL, Kim JJ, Min BH. Effect of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility during upper endoscopy in Asian patients with diabetes. World J Diabetes 2025; 16(12): 112694
- URL: https://www.wjgnet.com/1948-9358/full/v16/i12/112694.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i12.112694
